title: Cervical corpectomy with ultra-low-dose rhBMP-2 in high-risk patients: 5-year outcomes.
abstract: Twenty-four consecutive patients with cervical spondylosis who were treated with cervical corpectomy and recombinant human bone morphogenetic protein-2 (rhBMP-2) with standalone anterior instrumentation were evaluated. Mean number of levels fused was 2.4. There were significant improvements in visual analog scale neck pain and Oswestry Disability Index scores and cervical lordosis. Cervical corpectomy with a lower dose of rhBMP-2 was found to be safe and efficacious for patients who are at a higher risk for pseudarthrosis.
authors.forename: Sina
authors.initials: S
authors.lastname: Pourtaheri
authors.forename: Arash
authors.initials: A
authors.lastname: Emami
authors.forename: Ki
authors.initials: K
authors.lastname: Hwang
authors.forename: Jesse
authors.initials: J
authors.lastname: Allert
authors.forename: Alex
authors.initials: A
authors.lastname: Brothers
authors.forename: Kimona
authors.initials: K
authors.lastname: Issa
authors.forename: Michael A
authors.initials: MA
authors.lastname: Mont
mesh_terms: D000368:Aged; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage*; D002574:Cervical Vertebrae / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011542:Pseudarthrosis / Q000517:prevention & control; D011994:Recombinant Proteins / Q000008:administration & dosage; D013123:Spinal Fusion; D055009:Spondylosis / Q000628:therapy*; D016212:Transforming Growth Factor beta / Q000008:administration & dosage*
chemical_list: D055396:Bone Morphogenetic Protein 2; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2